Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells
Open accessThe DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
This report addresses whether small molecules can deplete FoxP3-expressing regulatory T (T reg) cells, thereby augmenting antitumor immunity. Imatinib, a tyrosine kinase inhibitor of oncogenic BCR-ABL protein expressed by chronic myelogenous leukemia (CML) cells, possesses off-targets including LCK expressed in T cells. We showed that imatinib-treated CML patients in complete molecular remission (CMR) exhibited selective depletion of effector T reg (eT reg) cells and significant increase in effector/memory CD8+ T cells while non-CMR patients did not. Imatinib at CML-therapeutic concentrations indeed induced apoptosis specifically in eT reg cells and expanded tumor antigen-specific CD8+ T cells in vitro in healthy individuals and melanoma patients, and suppressed colon tumor growth in vivo in mice. Mechanistically, because of FoxP3-dependent much lower expression of LCK and ZAP-70 in T reg cells compared with other T cells, imatinib inhibition of LCK further reduced their TCR signal intensity, rendering them selectively susceptible to signal-deprived apoptotis. Taken together, eT reg cell depletion by imatinib is instrumental in evoking effective immune responses to various cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









![Figure S5. Antitumor effect by imatinib in mice and molecular targets of imatinib in humans. (A) Total cell numbers of CD8+ and CD4+ T cells in the tumor (top) or the spleen (bottom) of CT26-inoculated BALB/c mice 3 d after the last imatinib treatment (15 d after tumor inoculation) as in Fig. 5 A. (B) The frequency and ratio of T reg cells and CD8+ T cells in Fig. 5 B. (C) Representative staining of Ki-67 and Foxp3 for CellTrace Violet+ T reg cells cultured with or without 10 µM imatinib and 5 U/ml IL-2 for 4 d. CD4+ Foxp3+ (GFP+) T reg cells from Foxp3-IRES-GFP reporter mice were sorted and labeled with CellTrace Violet before the culture (n = 3). Percentages of Ki-67+ cells (left) or mean fluorescence intensity of Foxp3 (right) are indicated in the plots. (D) Gene expression levels of putative targets of imatinib, including ABL1, ABL2, KIT, PDGFRA, LCK, NQO2,and DDR1 in human CD4+ or CD8+ T cells by deepCAGE (Cap Analysis of Gene Expression) database (CNhs 13223 and CNhs 12201). (E) LCK mRNA expressions in naive and effector subsets of CD8+ T, CD4+ T, and T reg cells prepared from PBMCs of healthy donors (n = 6). LCK mRNA levels relative to GAPDH were measured by quantitative real-time PCR. (F) FoxP3 binding near the promoter regions of human PIK3CD (gene encoding phosphatidylinositol-4,5-bisphosphate 3-kinase p110δ [PI3Kδ]) and PTPRC (gene encoding protein tyrosine phosphatase, receptor type C [CD45]) genes. The arrows indicate transcription start sites, boxes indicate exons, and peaks indicate FoxP3-binding sites from SRA data analysis (SRX060160; Birzele et al., 2011). (G) Signal intensities of pY394-LCK and total LCK protein with or without 10 µM imatinib in Fig. 6 C. AU, arbitrary unit. Error bars indicate means ± SD. Data are pooled from at least two independent experiments. Statistical significance was evaluated by two-sided Student’s t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001.](https://figures.cochat.ai/paper-figures/5275af670cc04950836f4392cde8e802/tyrosine-kinase-inhibitor-imatinib-augments-tumor-immunity-by-depleting-effector-figure-10.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Imatinib was arguably the first targeted anticancer agent to demonstrate immunostimulatory effects that are directly linked to NK-cell activation”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Tanaka et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
Sallusto, F., Lenig, D., Förster, R., Lipp, M., & Lanzavecchia, A. (1999) · Nature · doi:10.1038/44385 · Cited by 5,846 · cited 1×
“Analyses of other T cells, in particular CD8+ T cells, revealed that CML patients in CMR possessed significantly higher frequencies and numbers of central memory (CCR7+CD45RA−) and effector memory (CCR7−CD45RA−) CD8+ T cells (Sallusto et al., 1999), with reduction of naive T (CCR7+CD45RA+) cells and terminally differe…”
ResultRegulatory T Cells and Immune Tolerance
Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008) · Cell · doi:10.1016/j.cell.2008.05.009 · Cited by 5,325
Self-citationDruker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 2×
“In accordance with these findings, CD8+ T cells expressing coinhibitory molecules such as PD-1 and LAG-3, but not Tim-3 or CTLA-4, suggestive of an exhausted state (Wherry, 2011), were more abundant in non-CMR patients compared with healthy”
ResultRegulatory T cells: mechanisms of differentiation and function
Josefowicz, S. Z., Lu, L.-F., & Rudensky, A. Y. (2012) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141623 · Cited by 2,866
FOXP3+ regulatory T cells in the human immune system
Sakaguchi, S., Miyara, M., Costantino, C. M., & Hafler, D. A. (2010) · Nature Reviews Immunology · doi:10.1038/nri2785 · Cited by 2,439 · cited 1×
“…(Fr. III), which appear to be activated conventional T (T conv) cells transiently expressing FoxP3 at a low level, hardly exhibiting suppressive activity, and capable of secreting pro-inflammatory cytokines (Miyara et al., 2009; Saito et al., 2016; Sakaguchi et al., 2010; Sugiyama et al., 2013).”
BackgroundSelf-citationSato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372 · cited 1×
“significantly correlated with poor prognosis in various cancers (Bates et al., 2006; Curiel et al., 2004; Sasada et al., 2003; Sato et al., 2005).”
BackgroundSelf-citationMiyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., Taflin, C., Heike, T., Valeyre, D., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.03.019 · Cited by 2,291 · cited 2×
“…eT reg cells were physiologically in a more active proliferative state than other T reg cells or T conv cells as shown with freshly isolated eT reg cells or after in vitro culture with IL-2 without exogenous TCR stimulation (Levine et al., 2014; Miyara et al., 2009; Vahl et al., 2014; Fig.”
BackgroundSelf-citationEuropean LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Guilhot, F., et al. (2013) · Blood · doi:10.1182/blood-2013-05-501569 · Cited by 1,987 · cited 1×
“There were no significant differences between CMR and non-CMR patients in clinical parameters including CML risk score, imatinib treatment duration, and median time required for complete cytogenetic responses (Shinohara et al., 2013; Baccarani et al., 2013; Table 2).”
BackgroundA promoter-level mammalian expression atlas
The FANTOM Consortium and the RIKEN PMI and CLST (DGT) (2014) · Nature · doi:10.1038/nature13182 · Cited by 1,982
Self-citationRegulatory T cells in cancer immunotherapy
Tanaka, A., & Sakaguchi, S. (2017) · Cell Research · doi:10.1038/cr.2016.151 · Cited by 1,860 · cited 1×
“As illustrations of this undesirable role of T reg cells, they abundantly infiltrate into tumor tissues (Nishikawa and Sakaguchi, 2014; Tanaka and Sakaguchi, 2017), and a high frequency of Foxp3+ T reg cells or a high ratio of Foxp3+ cells to CD8+ T cells in the tumor tissue is”
BackgroundSelf-citationRegulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice
Kim, J. M., Rasmussen, J. P., & Rudensky, A. Y. (2007) · Nature Immunology · doi:10.1038/ni1428 · Cited by 1,820
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Saglio, G., Kim, D.-W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., Pasquini, R., Clark, R. E., Hochhaus, A., Hughes, T. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912614 · Cited by 1,678
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Kantarjian, H., Shah, N. P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasquini, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002315 · Cited by 1,589
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492 · cited 1×
“In addition, nilotinib, another BCR-ABL inhibitor with weaker off-target effects and better CML-killing activity than imatinib (Weisberg et al., 2005; Weisberg et al., 2007), was apparently less potent in reducing eT reg cells in a limited number of CML patients who had been treated with nilotinib alone or switched fr…”
BackgroundShimizu, J., Yamazaki, S., & Sakaguchi, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.10.5211 · Cited by 1,491 · cited 1×
“For example, depletion of CD25high T reg cells in tumor-bearingmice by anti-CD25 antibody treatment potently expanded tumorinfiltrating CD8+ T cells with strong tumor-specific killing activity, eradicating tumors (Onizuka et al., 1999; Shimizu et al., 1999).”
BackgroundSelf-citationAutoimmune disease as a consequence of developmental abnormality of a T cell subpopulation.
Asano, M., Toda, M., Sakaguchi, N., & Sakaguchi, S. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.2.387 · Cited by 1,330
Self-citationOnizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T., & Nakayama, E. (1999) · PubMed · Cited by 1,255
Self-citationBates, G. J., Fox, S. B., Han, C., Leek, R. D., Garcia, J. F., Harris, A. L., & Banham, A. H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9584 · Cited by 1,200
Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease
Lahl, K., Loddenkemper, C., Drouin, C., Freyer, J., Arnason, J., Eberl, G., Hamann, A., Wagner, H., Huehn, J., & Sparwasser, T. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061852 · Cited by 924 · cited 1×
“Moreover, selective depletion of Foxp3-expressing T reg cells in adult mice for a limited period is able to induce various autoimmunities (Asano et al., 1996; Kim et al., 2007; Lahl et al., 2007).”
BackgroundTwo FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., et al. (2016) · Nature Medicine · doi:10.1038/nm.4086 · Cited by 871
Self-citationOhkura, N., Hamaguchi, M., Morikawa, H., Sugimura, K., Tanaka, A., Ito, Y., Osaki, M., Tanaka, Y., Yamashita, R., Nakano, N., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.09.010 · Cited by 754
Self-citationRegulatory T cells in cancer immunotherapy
Nishikawa, H., & Sakaguchi, S. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.12.005 · Cited by 705
Self-citationMolldrem, J. J., Lee, P. P., Wang, C., Felio, K., Kantarjian, H. M., Champlin, R. E., & Davis, M. M. (2000) · Nature Medicine · doi:10.1038/79526 · Cited by 672
Ishida, T., Joh, T., Uike, N., Yamamoto, K., Utsunomiya, A., Yoshida, S., Saburi, Y., Miyamoto, T., Takemoto, S., Suzushima, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.3472 · Cited by 657
Weisberg, E., Manley, P. W., Cowan-Jacob, S. W., Hochhaus, A., & Griffin, J. D. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2126 · Cited by 636 · cited 2×
“In addition, nilotinib, another BCR-ABL inhibitor with weaker off-target effects and better CML-killing activity than imatinib (Weisberg et al., 2005; Weisberg et al., 2007), was apparently less potent in reducing eT reg cells in a limited number of CML patients who had been treated with nilotinib alone or switched fr…”
BackgroundSugiyama, D., Nishikawa, H., Maeda, Y., Nishioka, M., Tanemura, A., Katayama, I., Ezoe, S., Kanakura, Y., Sato, E., Fukumori, Y., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1316796110 · Cited by 627 · cited 8×
“…T reg cells, sorted cells were labeled with CellTrace Violet Cell proliferation dye (Thermo Fisher) and cultured for 4 d. Assessment of antigen-specific CD8+ T cells Antigen-specific CD8+ T cells were induced as described previously (Ha et al., 2019; Sugiyama et al., 2013), with some modifications.”
BackgroundMethodInfluentialSelf-citationFc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.010 · Cited by 592
TCR Signaling: Mechanisms of Initiation and Propagation
Courtney, A. H., Lo, W.-L., & Weiss, A. (2018) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2017.11.008 · Cited by 571
Continuous requirement for the TCR in regulatory T cell function
Levine, A. G., Arvey, A., Jin, W., & Rudensky, A. Y. (2014) · Nature Immunology · doi:10.1038/ni.3004 · Cited by 521
Balachandran, V. P., Cavnar, M. J., Zeng, S., Bamboat, Z. M., Ocuin, L. M., Obaid, H., Sorenson, E. C., Popow, R., Ariyan, C., Rossi, F., et al. (2011) · Nature Medicine · doi:10.1038/nm.2438 · Cited by 521
Sasada, T., Kimura, M., Yoshida, Y., Kanai, M., & Takabayashi, A. (2003) · Cancer · doi:10.1002/cncr.11618 · Cited by 484 · cited 1×
“significantly correlated with poor prognosis in various cancers (Bates et al., 2006; Curiel et al., 2004; Sasada et al., 2003; Sato et al., 2005).”
BackgroundNY‐ESO‐1: Review of an Immunogenic Tumor Antigen
(2006) · Advances in Cancer Research · doi:10.1016/s0065-230x(06)95001-5 · Cited by 405
Self-citationConstitutively Active Lck Kinase in T Cells Drives Antigen Receptor Signal Transduction
Nika, K., Soldani, C., Salek, M., Paster, W., Gray, A., Etzensperger, R., Fugger, L., Polzella, P., Cerundolo, V., Dushek, O., et al. (2010) · Immunity · doi:10.1016/j.immuni.2010.05.011 · Cited by 355
Insights into the initiation of TCR signaling
Chakraborty, A. K., & Weiss, A. (2014) · Nature Immunology · doi:10.1038/ni.2940 · Cited by 353
Continuous T Cell Receptor Signals Maintain a Functional Regulatory T Cell Pool
Vahl, J. C., Drees, C., Heger, K., Heink, S., Fischer, J. C., Nedjic, J., Ohkura, N., Morikawa, H., Poeck, H., Schallenberg, S., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.012 · Cited by 318 · cited 3×
“…eT reg cells were physiologically in a more active proliferative state than other T reg cells or T conv cells as shown with freshly isolated eT reg cells or after in vitro culture with IL-2 without exogenous TCR stimulation (Levine et al., 2014; Miyara et al., 2009; Vahl et al., 2014; Fig.”
BackgroundSelf-citationImagawa, J., Tanaka, H., Okada, M., Nakamae, H., Hino, M., Murai, K., Ishida, Y., Kumagai, T., Sato, S., Ohashi, K., et al. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00196-9 · Cited by 306
Seggewiss, R. (2005) · Blood · doi:10.1182/blood-2004-07-2527 · Cited by 290 · cited 2×
“Imatinib killed all these T cell subpopulations at higher doses well above its therapeutic concentration, indicative of its immunosuppressive activity at high doses (Seggewiss et al., 2005).”
BackgroundTarget spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib
Hantschel, O., Rix, U., & Superti-Furga, G. (2008) · Leukemia & Lymphoma · doi:10.1080/10428190801896103 · Cited by 256
Ha, D., Tanaka, A., Kibayashi, T., Tanemura, A., Sugiyama, D., Wing, J. B., Lim, E. L., Teng, K. W. W., Adeegbe, D., Newell, E. W., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1812186116 · Cited by 205 · cited 3×
“…T reg cells, sorted cells were labeled with CellTrace Violet Cell proliferation dye (Thermo Fisher) and cultured for 4 d. Assessment of antigen-specific CD8+ T cells Antigen-specific CD8+ T cells were induced as described previously (Ha et al., 2019; Sugiyama et al., 2013), with some modifications.”
BackgroundMethodSelf-citationMorikawa, H., & Sakaguchi, S. (2014) · Immunological Reviews · doi:10.1111/imr.12174 · Cited by 176
Self-citationRomero, P., Gervois, N., Schneider, J., Escobar, P., Valmori, D., Pannetier, C., Steinle, A., Wolfel, T., Lienard, D., Brichard, V, et al. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.5.2366 · Cited by 168
Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo
Dietz, A. B., Souan, L., Knutson, G. J., Bulur, P. A., Litzow, M. R., & Vuk-Pavlović, S. (2004) · Blood · doi:10.1182/blood-2003-12-4266 · Cited by 166
Gannagé, M., Abel, M., Michallet, A., Delluc, S., Lambert, M., Giraudier, S., Kratzer, R., Niedermann, G., Saveanu, L., Guilhot, F., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.8210 · Cited by 112
Lck is a key target of imatinib and dasatinib in T-cell activation
Lee, K. C., Ouwehand, I., Giannini, A. L. M., Thomas, N. S. B., Dibb, N. J., & Bijlmakers, M.-J. (2010) · Leukemia · doi:10.1038/leu.2010.11 · Cited by 91
Development and dynamics of robust T-cell responses to CML under imatinib treatment
Chen, C. I.-U., Maecker, H. T., & Lee, P. P. (2008) · Blood · doi:10.1182/blood-2007-12-128397 · Cited by 85
Next-generation insights into regulatory T cells: expression profiling and FoxP3 occupancy in Human
Birzele, F., Fauti, T., Stahl, H., Lenter, M. C., Simon, E., Knebel, D., Weith, A., Hildebrandt, T., & Mennerich, D. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr444 · Cited by 84
Shinohara, Y., Takahashi, N., Nishiwaki, K., Hino, M., Kashimura, M., Wakita, H., Hatano, Y., Hirasawa, A., Nakagawa, Y., Itoh, K., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.085167 · Cited by 31 · cited 3×
“Among them, 51 patients were in CMR (i.e., no detectable BCR-ABL mRNA by PCR), while 42 patients were in non-CMR (i.e., detectable BCR-ABL mRNA despite cytogenetic nondetection of leukemic cells; Table 1 and Shinohara et al., 2013 for detailed patients’ information).”
BackgroundMethodSelf-citation
Cited by
Regulatory T Cells and Human Disease
Sakaguchi, S., Mikami, N., Wing, J. B., Tanaka, A., Ichiyama, K., & Ohkura, N. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041717 · Cited by 1,120
“Notably, long-term imatinib-treated CML patients in complete molecular remission with no detectable BCR-ABLmRNA in the blood showed selective depletion of FoxP3+ effector Tregs, whereas those who failed inmolecular remission did not (191).”
BackgroundSelf-citationLi, C., Jiang, P., Wei, S., Xu, X., & Wang, J. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01234-1 · Cited by 921
“Mechanistically, because of the much lower expression of Foxp3dependent Lck and ZAP-70 in Tregs compared with other T cells, imatinib inhibition of Lck also reduced their TCR signal intensity, rendering them selectively susceptible to signal-deprived apoptosis [147].”
BackgroundTumor-infiltrating regulatory T cells as targets of cancer immunotherapy
Tay, C., Tanaka, A., & Sakaguchi, S. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.014 · Cited by 580
Self-citationKoyama, S., & Nishikawa, H. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002591 · Cited by 305
“124 The PI3K signaling pathway is also essential for T cell survival and function.”
BackgroundSelf-citationTherapeutic targeting of regulatory T cells in cancer
Shan, F., Somasundaram, A., Bruno, T. C., Workman, C. J., & Vignali, D. A. A. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2022.06.008 · Cited by 244
Metadata
- Authors
- Tanaka, A., Nishikawa, H., Noguchi, S., Sugiyama, D., Morikawa, H., Takeuchi, Y., Ha, D., Shigeta, N., Kitawaki, T., Maeda, Y., Saito, T., Shinohara, Y., Kameoka, Y., Iwaisako, K., Monma, F., Ohishi, K., Karbach, J., Jäger, E., Sawada, K., Katayama, N., Takahashi, N., & Sakaguchi, S.
- Affiliations
- Immunology Frontier Research Center, The University of Osaka (JP)
- Akita University (JP)
- Kyoto University (JP)
- Mie University (JP)
- Krankenhaus Nordwest (DE)
- Corresponding author
- Sakaguchi, Shimon
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2019-11-08
- Volume
- 217
- Issue
- 2
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC7041710
- OpenAlex
- W2989109767
- Cited by
- 96
- References
- 51
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 11 · 2023: 18 · 2022: 19 · 2021: 19 · 2020: 7
- FWCI
- 4.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- Kyoto University Research Information Repository (Kyoto University) (submittedVersion, cc-by-nc-sa)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology of Japan (16H06295, 26253030, 23300354, 26290054, 26860331, 17K15723, 17H06162)
- Core Research for Evolutional Science and Technology
- Japan Science and Technology Agency (17gm0410016)
- Japan Agency for Medical Research and Development (18gm0010005, 18cm0106303)
- Ministry of Health, Labor, and Welfare of Japan (H24-Clinical Cancer Research-general-006)
- Cancer Research Institute
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- imatinib, tyrosine kinase inhibitors, regulatory T cells, Foxp3, Lck, ZAP-70, T cell receptor signaling, apoptosis, antitumor immunity, chronic myeloid leukemia, complete molecular remission, CD8+ T cells, melanoma, off-target effects
- MeSH terms
- Imatinib Mesylate, Animals, Colonic Neoplasms, Disease Models, Animal, Female, Humans, Immunity, Mice, Inbred BALB C, Mice, Transgenic, Receptors, Antigen, T-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Mice, SCID, Treatment Outcome, Apoptosis, CD8-Positive T-Lymphocytes, Lymphocyte Specific Protein Tyrosine Kinase p56(lck), Cell Line, Tumor, Protein Kinase Inhibitors, T-Lymphocytes, Regulatory, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.